ET
IBRX icon

Entropy Technologies’s ImmunityBio IBRX Stock Holding History

Entropy Technologies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Buy
+55,783
New +$422K 0.02% 669

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Entropy Technologies's IBRX Position: Q2 2026 in Review

Entropy Technologies opened a new position in ImmunityBio (IBRX) in Q2 2026: 55,783 shares worth $488K. The stake represents 0.02% of the portfolio and ranks #669 among its holdings.

404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Entropy Technologies held 55,783 shares of ImmunityBio worth $488K as of Q2 2026.
  • ImmunityBio was a new Entropy Technologies position in Q2 2026.
  • ImmunityBio made up 0.02% of Entropy Technologies's portfolio in Q2 2026, its #669 holding.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.